参麦宁肺方治疗223例新冠病毒感染者的真实世界研究  

Shenmai Ningfei Decoction in the Treatment of 223 Cases of COVID-19: a Real World Study

作　　者：廖春燕[1] 徐丹[1] 李争[1] 翟豫疆[1] 江道斌[1] 王玲[1] 朱玉龙[1] 马红霞[1] 舒占军 孙奇[1] 荆晶[1] 李茜[1] 李风森[1] Liao Chunyan;Xu Dan;Li Zheng;Zhai Yujiang;Jiang Daobin;Wang Ling;Zhu Yulong;Ma Hongxia;Shu Zhanjun;Sun Qi;Jing Jing;Li Qian;Li Fengsen(The Fourth Affiliated Hospital of Xinjiang Medical University,Urumqi 830000,China)

机构地区：[1]新疆医科大学第四附属医院,乌鲁木齐830000

出　　处：《世界科学技术-中医药现代化》2022年第3期996-1005,共10页Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology

基　　金：新疆维吾尔自治区科学技术厅新疆公共卫生关键技术研发与防疫体系建设专项(2020A03004):新冠肺炎、新疆地方高发传染病及其并发症的中西医结合防治研究,负责人:李风森。

摘　　要：目的基于回顾性真实世界评估参麦宁肺方对新型冠状病毒肺炎核酸检测阳性患者的治疗作用及安全性。方法研究对象为2020年7月17日至2020年12月4日于新疆维吾尔自治区新冠肺炎患者定点医院收治的新冠病毒核酸检测阳性的患者,根据药物使用情况分为参麦宁肺方治疗组(参麦组)223例,连花清瘟胶囊治疗组(连花组)132例,连花清瘟胶囊+参麦宁肺方治疗组(联合组)201例。观察治疗前、治疗后第7天,第14天血清炎症因子IFN-γ、IL-4、IL-6、IL-10、IL-17、淋巴细胞、CD3^(+)T、CD4^(+)T、CD8^(+)T淋巴细胞、新冠肺炎病毒特异性抗体IgM、IgG、新冠病毒核酸CT值及临床分型转重率的变化。结果参麦组、连花组、联合组患者年龄、吸烟无差异,临床分型分别以无症状型(91.48%)、普通型(55.30%)、无症状型(65.67%)为主。炎症因子:治疗前IL-10、IL-17三组无差异,参麦组IFN-γ和IL-4最低,联合组IL-6最低,治疗第7天三组患者IFN-γ均较治疗前下降,参麦组下降最明显;IL-6在参麦组、联合组增高,连花组下降;IL-10在参麦组和联合组下降,联合组变化不明显;三组患者经治疗后IL-4、IL-17均有下降趋势。淋巴细胞和特异性抗体:外周血淋巴细胞计数治疗前参麦组较连花组和联合组高,治疗后第7天、第14天三组患者淋巴细胞计数均较治疗前上升,参麦组上升趋势最明显;治疗前CD3^(+)T淋巴细胞计数参麦组高于连花组和联合组,治疗第7天、第14天参麦组CD3^(+)T、CD4^(+)T、CD8^(+)T细胞数均有下降趋势,而连花组、联合组CD3^(+)T、CD4^(+)T、CD8^(+)T细胞均有上升趋势;治疗前新冠肺炎病毒特异性IgM、IgG抗体参麦组和联合组较连花组浓度低,治疗第7天、第14天参麦组、联合组IgM、IgG抗体浓度增长较连花组缓慢,治疗第14天,参麦组8.58(2.95,17.75)IgG抗体浓度最低。病毒核酸检测CT值和转重率:三组患者新冠病毒OR基因CT值治疗前后均无�Objective To evaluate the efficacy and safety of Shenmai Ningfei decoction for COVID-19 nucleic acid positive patients based on a retrospective real-world study.Methods The subjects of this study were patients with a positive nucleic acid test of COVID-19 who were admitted to the designated hospital of COVID-19 patients in Xinjiang Uygur Autonomous Region from July 17,2020 to December 4,2020.According to the drug use,they were divided into Shenmai Ningfei decoction treatment group(Shenmai group)of 223 cases,Lianhua Qingwen capsule treatment group(Lianhua group)of 132 patients,and Lianhua Qingwen Capsule+Shenmai ningfei treatment group(combined group)of 201 cases.The CT values of serum inflammatory cytokines IFN-γ,IL-4,IL-6,IL-10,IL-17,lymphocytes,CD3^(+)T,CD4^(+)T,CD8^(+)T lymphocytes,COVID-19 virus-specific antibodies IgM,IgG,COVID-19 nucleic acid,and the conversion rate of clinical typing were observed before treatment,7 days after treatment and 14 days after treatment.Results There was no difference in age and smoking in the Shenmai group,Lianhua group and combined group,and the clinical classification was mainly asymptomatic(91.48%),common(55.30%)and asymptomatic(65.67%),respectively.Inflammatory factors:before treatment,there was no difference in IL-10 and IL-17 among the three groups.IFN-γand IL-4 were the lowest in the Shenmai group,and IL-6 was the weakest in the combined group.On the 7^(th) day of treatment,IFN-γin all three groups decreased compared with before treatment,and the decrease was most obvious in the Shenmai group.IL-6 was increased in the Shenmai group and combined group but decreased in the Lianhua group.IL-10 decreased in the Shenmai group and the combined group,but no significant change in the combined group.After treatment,IL-4 and IL-17 all showed a decreasing trend in the three groups.Lymphocyte and specific antibody:Before treatment,peripheral blood lymphocyte count in the Shenmai group was higher than that in the continuous flower and combined groups.On the 7^(th) and 14^(th) day

关 键 词：新型冠状病毒肺炎 参麦宁肺方 中医药 真实世界研究 

分 类 号：R285.5[医药卫生—中药学]